A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07581184
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of [225Ac]Ac-AKY-2519 in participants with metastatic castration-resistant prostate cancer (mCRPC) with and without prior exposure to 177Lu-PSMA-617 (PLUVICTO™).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Castration Resistant Metastatic Prostate Cancer
- Prostate Cancer
- mCRPC (Metastatic Castration-resistant Prostate Cancer)
- mCRPC
- B7H3
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Aktis Oncology, Inc.
- Last updated on ClinicalTrials.gov
- September 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Hoag Memorial Hospital Presbyterian · Irvine, CA
Florida · 1
- Biogenix Molecular, LLC · Miami, FL
Kansas · 1
- University of Kansas Medical Center · Kansas City, KS
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Michigan · 1
- BAMF Health · Grand Rapids, MI
Nebraska · 1
- XCancer · Omaha, NE
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.